Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead program is REL-1017, is a new chemical entity and novel N-methyl-D-aspartate receptor channel blocker for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is based in Coral Gables, Florida.